• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Dyne Therapeutics Inc.

    11/14/24 6:34:59 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DYN alert in real time by email
    SC 13G 1 p24-3257sc13g.htm

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

    Dyne Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    26818M108

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 26818M10813GPages 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    RTW Investments, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    6,818,641 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    6,818,641 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,818,641 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.8%

    12

    TYPE OF REPORTING PERSON

    PN, IA

             

     

    CUSIP No. 26818M10813GPages 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Roderick Wong, M.D.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    6,818,641 Shares

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    6,818,641 Shares

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,818,641 Shares

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.8%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 26818M10813GPages 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Dyne Therapeutics, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company's principal executive offices are located at 1560 Trapelo Road, Waltham, Massachusetts 02451.

     

    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by:

     

      (i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership, and the investment adviser to certain funds (the "RTW Funds"), with respect to the Shares (as defined in Item 2(d) below) directly held by the RTW Funds; and
         
      (ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.

     

    Item 2(c). CITIZENSHIP:

     

      RTW Investments is a Delaware limited partnership.  Dr. Wong is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, par value $0.0001 per share (the "Shares").

     

     

    CUSIP No. 26818M10813GPages 5 of 7 Pages

     

    Item 2(e). CUSIP NUMBER:
       
      26818M108

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:                                                                                        

     

    Item 4. OWNERSHIP:

     

        The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
         
        The percentages set forth herein are calculated based upon 100,400,798 Shares outstanding as of August 9, 2024, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 12, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
       
      Not applicable.

     

     

    CUSIP No. 26818M10813GPages 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
       
      See Item 2.  The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP:
       
      Not applicable.

     

    Item 10. CERTIFICATION:

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 26818M10813GPages 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

     

    RTW INVESTMENTS, LP
         
         
    By: /s/ Roderick Wong, M.D.  
    Name: Roderick Wong, M.D.  
    Title: Managing Partner  
         
         
         
    /s/ Roderick Wong, M.D.  
    RODERICK WONG, M.D.  
         

     

    Get the next $DYN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYN

    DatePrice TargetRatingAnalyst
    10/10/2025Outperform → Perform
    Oppenheimer
    8/25/2025$35.00Outperform → Strong Buy
    Raymond James
    6/24/2025$13.00Mkt Perform
    Bernstein
    6/11/2025$37.00Outperform
    Raymond James
    6/2/2025$34.00Outperform
    Oppenheimer
    5/29/2025$46.00Outperform
    Evercore ISI
    3/12/2025$50.00Outperform
    BMO Capital Markets
    3/7/2025$50.00Sector Outperform
    Scotiabank
    More analyst ratings

    $DYN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Posner Brian S

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    10/2/25 4:18:07 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Posner Brian S claimed ownership of 8,500 shares (SEC Form 3)

    3 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    10/2/25 4:13:03 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Cox John sold $35,402 worth of shares (2,640 units at $13.41), decreasing direct ownership by 1% to 199,539 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    9/9/25 4:31:26 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dyne Therapeutics downgraded by Oppenheimer

    Oppenheimer downgraded Dyne Therapeutics from Outperform to Perform

    10/10/25 8:28:51 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics upgraded by Raymond James with a new price target

    Raymond James upgraded Dyne Therapeutics from Outperform to Strong Buy and set a new price target of $35.00

    8/25/25 8:07:36 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Dyne Therapeutics with a new price target

    Bernstein initiated coverage of Dyne Therapeutics with a rating of Mkt Perform and set a new price target of $13.00

    6/24/25 8:00:58 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Cox John gifted 40,000 shares and bought $911,000 worth of shares (100,000 units at $9.11), increasing direct ownership by 42% to 202,179 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    7/15/25 5:11:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Cox John bought $1,057,216 worth of shares (32,000 units at $33.04) (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    9/4/24 5:42:18 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kersten Dirk bought $29,999,988 worth of shares (1,714,285 units at $17.50) (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    1/11/24 4:31:55 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

    - Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvements in overall disease burden reported by both patients and physicians - WALTHAM, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced additional one-year data from its ongoing Phase 1/2 ACHIEVE clinical trial of zeleciment basivarsen (z-basivarsen, formerly known as DYNE-101), in patients with myotonic dystrophy

    10/6/25 6:01:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Appoints Brian Posner to its Board of Directors

    WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. "Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped b

    10/2/25 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy

    - Data from ongoing DELIVER trial demonstrated sustained functional improvement through 18 months; results from Registrational Expansion Cohort expected late 2025 - WALTHAM, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage company, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted Orphan Drug designation for DYNE-251 in individuals with Duchenne muscular dystrophy (DMD) who have mutations in the DMD gene that are amenable to exon 51 skipping. DYNE-251 is being evaluated in the ongoing Phase 1/2 DELIVER global clinical trial. "In the DELIVER trial, we've seen unprecedented and sustained functional i

    9/29/25 8:35:12 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    SEC Filings

    View All

    Dyne Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)

    10/2/25 4:10:27 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    9/5/25 4:14:24 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    9/4/25 4:45:12 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Leadership Updates

    Live Leadership Updates

    View All

    Dyne Therapeutics Appoints Brian Posner to its Board of Directors

    WALTHAM, Mass., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Brian Posner to its Board of Directors. Mr. Posner brings 35 years of executive, investment and board leadership expertise to the company. "Brian is joining our Board during a pivotal phase, as we transition to becoming a fully integrated biotechnology company poised to commercialize our first potential product in 2027," said Jason Rhodes, chairman of Dyne's Board of Directors and partner at Atlas Venture. "With a perspective shaped b

    10/2/25 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

    Brings a successful track record in clinical development and regulatory approval of innovative neuromuscular therapies Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer ("CMO"). Dr. Farwell joins Satellos from Dyne Therapeutics (NASDAQ:DYN), where he most recently served as CMO and medical advisor. "We are thrilled to welcome Dr. Farwell as our CMO," said Frank Gleeson, Satellos co-founder and CEO. "He brings deep expertise in global clinical development — p

    7/16/25 7:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Announces CEO Transition

    - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles

    3/25/24 7:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Financials

    Live finance-specific insights

    View All

    Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

    - Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase 1/2 ACHIEVE trial support vHOT as early indicator of clinical benefit with DYNE-101 in DM1 - - Ongoing Registrational Expansion Cohort in ACHIEVE trial to enroll 60 participants and include sites in U.S. - - Company to host an investor and analyst conference call today, June 17, at 8:00 a.m. ET - WALTHAM, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically

    6/17/25 7:00:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

    WALTHAM, Mass., June 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to provide an update on DYNE-101 in myotonic dystrophy type 1 (DM1) tomorrow, June 17, 2025, and to host a webcast at 8:00 a.m. ET. The company intends to issue a press release prior to the start of the event. Investor Conference Call and Webcast The live webcast will be available on the Events & Presentations page of the Investors & Media section of Dyne's website, and a replay will be accessible for 90 days followin

    6/16/25 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

    - DYNE-101 in DM1: Dyne plans to initiate global Registrational Expansion Cohort of ACHIEVE trial with registrational dose of 6.8 mg/kg Q8W following study data showing splicing correction and robust and sustained functional improvements; potential to support H1 2026 submission for U.S. Accelerated Approval - - DYNE-251 in Exon 51 DMD: Based on recent FDA feedback, pursuing U.S. Accelerated Approval with dystrophin as surrogate endpoint; data from ongoing Registrational Expansion Cohort in DELIVER trial expected late 2025 with potential to support early 2026 regulatory submission - - Investor event today, January 10th at 8:00 a.m. ET - WALTHAM, Mass., Jan. 10, 2025 (GLOBE NE

    1/10/25 6:30:00 AM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DYN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 5:46:12 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:32:40 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dyne Therapeutics Inc.

    SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)

    11/14/24 4:23:11 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care